Skip to main content
EU expands approval for Agilent's Opdivo companion Dx

European regulators have given Agilent Technologies expanded CE mark approval for its Dako PD-L1 IHC 28-8 pharmDx test for use in determining which urothelial cancer patients are most likely to benefit from Bristol-Myers Squibb's cancer drug Opdivo. The test is already approved for use in tumor cell PD-L1 expression for melanoma, non-squamous non-small cell lung cancer and squamous cell carcinoma of the head and neck.

Full Story: